Cargando…

FIP: a novel approach to vaccination: Proceedings from the 2nd International FCoV/FIP Symposium, Glasgow, 4–7 August 2002

Feline infectious peritonitis (FIP) is a fatal disease of cats. Early attempts at vaccination have been unsuccessful, some even serving to exacerbate the disease through antibody-dependent enhancement. Replication-incompetent feline foamy virus (FFV) transducing vectors are being developed as potent...

Descripción completa

Detalles Bibliográficos
Autores principales: German, A.C., Helps, C.R., Harbour, D.A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: ESFM and AAFP. Published by Elsevier Ltd. 2004
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129736/
https://www.ncbi.nlm.nih.gov/pubmed/15123157
http://dx.doi.org/10.1016/j.jfms.2003.08.010
_version_ 1783516853363015680
author German, A.C.
Helps, C.R.
Harbour, D.A.
author_facet German, A.C.
Helps, C.R.
Harbour, D.A.
author_sort German, A.C.
collection PubMed
description Feline infectious peritonitis (FIP) is a fatal disease of cats. Early attempts at vaccination have been unsuccessful, some even serving to exacerbate the disease through antibody-dependent enhancement. Replication-incompetent feline foamy virus (FFV) transducing vectors are being developed as potential vaccine agents, into which immunogenic fragments of feline coronavirus (FCoV) proteins will be inserted. To use a recombinant viral vector to express FCoV proteins, the agent chosen should be apathogenic and replication incompetent within the host following gene delivery. Spumaviruses confer several advantages over the more traditionally explored retroviral vectors. Stable helper cell line clones have been established by transfection of CRFK cells with FFV tas and assessed using β-galactosidase assays, PCR, immunofluorescence and western blotting. The generation of infectious virions using these cell lines has been investigated using tas-deleted FFV vectors containing the enhanced green fluorescent protein (eGFP) cassette.
format Online
Article
Text
id pubmed-7129736
institution National Center for Biotechnology Information
language English
publishDate 2004
publisher ESFM and AAFP. Published by Elsevier Ltd.
record_format MEDLINE/PubMed
spelling pubmed-71297362020-04-08 FIP: a novel approach to vaccination: Proceedings from the 2nd International FCoV/FIP Symposium, Glasgow, 4–7 August 2002 German, A.C. Helps, C.R. Harbour, D.A. J Feline Med Surg Article Feline infectious peritonitis (FIP) is a fatal disease of cats. Early attempts at vaccination have been unsuccessful, some even serving to exacerbate the disease through antibody-dependent enhancement. Replication-incompetent feline foamy virus (FFV) transducing vectors are being developed as potential vaccine agents, into which immunogenic fragments of feline coronavirus (FCoV) proteins will be inserted. To use a recombinant viral vector to express FCoV proteins, the agent chosen should be apathogenic and replication incompetent within the host following gene delivery. Spumaviruses confer several advantages over the more traditionally explored retroviral vectors. Stable helper cell line clones have been established by transfection of CRFK cells with FFV tas and assessed using β-galactosidase assays, PCR, immunofluorescence and western blotting. The generation of infectious virions using these cell lines has been investigated using tas-deleted FFV vectors containing the enhanced green fluorescent protein (eGFP) cassette. ESFM and AAFP. Published by Elsevier Ltd. 2004-04 2004-02-25 /pmc/articles/PMC7129736/ /pubmed/15123157 http://dx.doi.org/10.1016/j.jfms.2003.08.010 Text en Copyright © 2004 ESFM and AAFP. Published by Elsevier Ltd. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
German, A.C.
Helps, C.R.
Harbour, D.A.
FIP: a novel approach to vaccination: Proceedings from the 2nd International FCoV/FIP Symposium, Glasgow, 4–7 August 2002
title FIP: a novel approach to vaccination: Proceedings from the 2nd International FCoV/FIP Symposium, Glasgow, 4–7 August 2002
title_full FIP: a novel approach to vaccination: Proceedings from the 2nd International FCoV/FIP Symposium, Glasgow, 4–7 August 2002
title_fullStr FIP: a novel approach to vaccination: Proceedings from the 2nd International FCoV/FIP Symposium, Glasgow, 4–7 August 2002
title_full_unstemmed FIP: a novel approach to vaccination: Proceedings from the 2nd International FCoV/FIP Symposium, Glasgow, 4–7 August 2002
title_short FIP: a novel approach to vaccination: Proceedings from the 2nd International FCoV/FIP Symposium, Glasgow, 4–7 August 2002
title_sort fip: a novel approach to vaccination: proceedings from the 2nd international fcov/fip symposium, glasgow, 4–7 august 2002
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7129736/
https://www.ncbi.nlm.nih.gov/pubmed/15123157
http://dx.doi.org/10.1016/j.jfms.2003.08.010
work_keys_str_mv AT germanac fipanovelapproachtovaccinationproceedingsfromthe2ndinternationalfcovfipsymposiumglasgow47august2002
AT helpscr fipanovelapproachtovaccinationproceedingsfromthe2ndinternationalfcovfipsymposiumglasgow47august2002
AT harbourda fipanovelapproachtovaccinationproceedingsfromthe2ndinternationalfcovfipsymposiumglasgow47august2002